General Information of the Compound
Compound ID |
CP0085130
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
Show/Hide
|
||||||||||||||||||
Synonyms |
1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE
2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-
4I7U5C459M
720691-69-0
AK171368
AKOS025291102
AS-42474
BDBM50444496
CHEMBL3092650
GSK-239512
GSK239512
J3.497.402K
KS-0000063Q
MolPort-035-776-189
PMID29334795-Compound-23
SB16754
SCHEMBL167578
UNII-4I7U5C459M
YFRBKEVUUCQYOW-UHFFFAOYSA-N
ZINC3961802
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C23H27N3O2
|
||||||||||||||||||
Molecular Weight |
377.488
|
||||||||||||||||||
Canonical SMILES |
O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
Show/Hide
|
||||||||||||||||||
InChIKey |
YFRBKEVUUCQYOW-UHFFFAOYSA-N
|
||||||||||||||||||
CAS |
720691-69-0
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound
Drug 1 ( GSK239512 )
Drug Name | GSK239512 | ||
---|---|---|---|
Company | GSK | ||
Indication | |||
Target(s) |
Drug 2 ( PMID29334795-Compound-23 )
Drug Name | PMID29334795-Compound-23 | ||
---|---|---|---|
Company | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAMFORD, Mark, James DEAN, David, Kenneth SEHMI, Sanjeet, Singh WILSON, David, Matthew WITHERINGTON, Jason | ||
Indication | |||
Target(s) |